Literature DB >> 12773577

Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Kaye L Stenvers1, Melinda L Tursky, Kenneth W Harder, Nicole Kountouri, Supavadee Amatayakul-Chantler, Dianne Grail, Clayton Small, Robert A Weinberg, Andrew M Sizeland, Hong-Jian Zhu.   

Abstract

The type III transforming growth factor beta (TGFbeta) receptor (TbetaRIII) binds both TGFbeta and inhibin with high affinity and modulates the association of these ligands with their signaling receptors. However, the significance of TbetaRIII signaling in vivo is not known. In this study, we have sought to determine the role of TbetaRIII during development. We identified the predominant expression sites of TbetaRIII mRNA as liver and heart during midgestation and have disrupted the murine TbetaRIII gene by homologous recombination. Beginning at embryonic day 13.5, mice with mutations in TbetaRIII developed lethal proliferative defects in heart and apoptosis in liver, indicating that TbetaRIII is required during murine somatic development. To assess the effects of the absence of TbetaRIII on the function of its ligands, primary fibroblasts were generated from TbetaRIII-null and wild-type embryos. Our results indicate that TbetaRIII deficiency differentially affects the activities of TGFbeta ligands. Notably, TbetaRIII-null cells exhibited significantly reduced sensitivity to TGFbeta2 in terms of growth inhibition, reporter gene activation, and Smad2 nuclear localization, effects not observed with other ligands. These data indicate that TbetaRIII is an important modulator of TGFbeta2 function in embryonic fibroblasts and that reduced sensitivity to TGFbeta2 may underlie aspects of the TbetaRIII mutant phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773577      PMCID: PMC156130          DOI: 10.1128/MCB.23.12.4371-4385.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  65 in total

Review 1.  Controlling TGF-beta signaling.

Authors:  J Massagué; Y G Chen
Journal:  Genes Dev       Date:  2000-03-15       Impact factor: 11.361

Review 2.  Regulation of Smad activity.

Authors:  J L Wrana
Journal:  Cell       Date:  2000-01-21       Impact factor: 41.582

3.  Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.

Authors:  D Rotzer; M Roth; M Lutz; D Lindemann; W Sebald; P Knaus
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

4.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.

Authors:  K A Lewis; P C Gray; A L Blount; L A MacConell; E Wiater; L M Bilezikjian; W Vale
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

6.  Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers.

Authors:  S A Stacker; K Stenvers; C Caesar; A Vitali; T Domagala; E Nice; S Roufail; R J Simpson; R Moritz; T Karpanen; K Alitalo; M G Achen
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

7.  Epidermal growth factor impairs the cytochrome C/caspase-3 apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway.

Authors:  I Fabregat; B Herrera; M Fernández; A M Alvarez; A Sánchez; C Roncero; J J Ventura; A M Valverde; M Benito
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

Review 8.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

Authors:  C H Heldin; K Miyazono; P ten Dijke
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

9.  Murine betaglycan primary structure, expression and glycosaminoglycan attachment sites.

Authors:  M V Ponce-Castañeda; J Esparza-López; M M Vilchis-Landeros; V Mendoza; F López-Casillas
Journal:  Biochim Biophys Acta       Date:  1998-05-19

Review 10.  TGF-beta signal transduction.

Authors:  J Massagué
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  82 in total

1.  Competence of an artificial bent DNA as a transcriptional activator in mouse ES cells.

Authors:  Jun-ichi Tanase; Tasuku Mitani; Koji Udagawa; Jun-ichi Nishikawa; Takashi Ohyama
Journal:  Mol Biol Rep       Date:  2010-03-20       Impact factor: 2.316

Review 2.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

Review 3.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

Review 4.  Cell biology of embryonic migration.

Authors:  Satoshi Kurosaka; Anna Kashina
Journal:  Birth Defects Res C Embryo Today       Date:  2008-06

5.  Sequencing of TGF-beta pathway genes in familial cases of intracranial aneurysm.

Authors:  Teresa Santiago-Sim; Sumy Mathew-Joseph; Hariyadarshi Pannu; Dianna M Milewicz; Christine E Seidman; J G Seidman; Dong H Kim
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

Review 6.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

7.  Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Authors:  S J Cooper; H Zou; S N Legrand; L A Marlow; C A von Roemeling; D C Radisky; K J Wu; N Hempel; V Margulis; H W Tun; G C Blobe; C G Wood; J A Copland
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

8.  Proteolytic control of TGF-β co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics.

Authors:  Frédéric Delolme; Cyril Anastasi; Lindsay B Alcaraz; Valentin Mendoza; Sandrine Vadon-Le Goff; Maya Talantikite; Robin Capomaccio; Jimmy Mevaere; Laëtitia Fortin; Dominique Mazzocut; Odile Damour; Isabelle Zanella-Cléon; David J S Hulmes; Christopher M Overall; Ulrich Valcourt; Fernando Lopez-Casillas; Catherine Moali
Journal:  Cell Mol Life Sci       Date:  2014-09-27       Impact factor: 9.261

9.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

10.  Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling.

Authors:  Y-S Jang; G-Y Seo; J-M Lee; H-Y Seo; H-J Han; S-J Kim; B-R Jin; H-J Kim; S-R Park; K-J Rhee; W-S Kim; P-H Kim
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.